

Sigma-Tau Pharmaceuticals, Inc.

No Patient Should Be Overlooked



Our Mission Statement

Sigma-Tau seeks to contribute to the health and well-being of humanity through all of its actions, but primarily by developing or acquiring and making available products based on naturally occurring substances that enhance the body's ability to maintain a healthy state.





Sigma-Tau Pharmaceuticals, Inc.

Sigma-Tau Pharmaceuticals, Inc. was founded on a commitment to provide treatment for unmet medical needs. It is one of three U.S. subsidiaries of Sigma-Tau S.p.A., the leading research-based Italian pharmaceutical company, with subsidiaries worldwide. Founded in 1957, Sigma-Tau S.p.A. is the worldwide leader in carnitine and metabolic research and ranks among the top 25 niche companies in the world in patent activity. Sigma-Tau Pharmaceuticals, Inc. began commercial operations in the United States in 1989.





Products

Although our patient populations are small, we are committed to providing products that can improve the quality of life for those whose medical needs might not otherwise be met.

Our flagship product, Carnitor® (levocarnitine), is an FDA-approved treatment for carnitine deficiency in dialysis patients and patients with certain metabolic disorders. Another area of focus is the development of a new product, cysteamine eye drops, for the reduction of the cystine crystals that accumulate in the eyes of patients with cystinosis, a rare disorder that affects less than 300 people in the United States.

Although not considered an orphan drug, Sigma-Tau Pharmaceuticals, Inc. also produces Matulane® (procarbazine hydrochloride), a drug needed by many cancer patients diagnosed with Stage III and Stage IV Hodgkin's disease.



Education and Awards

The well-being of the patients who use our products is of the highest concern to Sigma-Tau Pharmaceuticals, Inc. We strive to maintain state-of-the-art scientific knowledge regarding the therapeutic action of our products and the conditions they treat.

Providing new or improved treatments for diseases that are complex and difficult to diagnose presents Sigma-Tau Pharmaceuticals, Inc. with the educational challenges of informing physicians and parents about medical symptoms and treatment options. No matter how small the patient population, we endeavor to foster consumer knowledge concerning the use of our products.

That is why we devote approximately 20% of our revenues to funding clinical research – a rate higher than the pharmaceutical industry average. In order to ensure that the research necessary to treat unmet medical needs is conducted, Sigma-Tau Pharmaceuticals, Inc. funds research in areas that will not necessarily provide an immediate return on investment. In fact, we have funded more than half of the published research on carnitine deficiency and the effects of carnitine supplementation.

Patient Assistance Programs

Always mindful of helping patients gain access to needed drugs, Sigma-Tau Pharmaceuticals funds patient assistance programs for our prescription products through the National Organization for Rare Disorders (NORD) to help ensure that underinsured and financially needy patients receive the products at little or no cost.



Young Investigator Awards

Helping ensure that future health care needs are not overlooked, Sigma-Tau Pharmaceuticals, Inc. encourages beginning physicians to pursue research programs in the areas of nephrology, the genetics of metabolism and child neurology. Each year, we award three fellowship grants to the young investigators who will discover tomorrow's medical breakthroughs and treatments. By providing financial support, we help ensure that physicians dedicated to research make a successful transition from medical residency to a hospital position with research orientation.

Claudio Cavazza Science Awards

Named in honor of Claudio Cavazza, Ph.D., president and chief executive officer of Sigma-Tau S.p.A., this annual award honors high school students who have shown an interest in pursuing a career in science. Through scholarship funding and internships, Sigma-Tau is helping to develop tomorrow's scientists and medical researchers.

We devote approximately 20% of our revenues to funding clinical research – a rate higher than the pharmaceutical average.



Sigma-Tau Pharmaceuticals, Inc. has been acknowledged for outstanding programs that foster the physical, emotional and intellectual development of young children.

Exceptional Parent

While we are dedicated to future growth and the ongoing distribution of our products, we are committed to meeting our patients' needs. We are proud to have received the EXCEPTIONAL PARENT Symbol of Excellence for our "*consistent and outstanding contributions to health care, particularly for people with disabilities and special health care needs.*"



Workplace Models of Excellence

Outstanding Efforts to Enhance Early Childhood Development ...

The National Healthy Mothers, Healthy Babies Coalition (HMHB) established the Workplace Models of Excellence to recognize family-friendly employers that are making an impact on maternal and child health. Sigma-Tau Pharmaceuticals, Inc. has been acknowledged for outstanding programs that foster the physical, emotional and intellectual development of young children.

As a corporation that dedicates itself to the treatment of diseases that are complex and difficult to diagnose, our promotion of comprehensive screening tests for newborns is an important part of the company's philosophy that "no patient be overlooked."


Employees of Sigma-Tau Pharmaceuticals, Inc. are provided with information about Comprehensive Newborn Screening (CNBS) options for metabolic disorders that occur in approximately one out of every 1,500 births. Since many states have not adopted CNBS, we work with private laboratories and fund the information and testing kits. This facilitates discussion among employees, their obstetricians, and other health care providers who will coordinate the newborn screening tests during the first day of a baby's life.






Pharmaceuticals for Unmet Patient Needs

At Sigma-Tau Pharmaceuticals, Inc., we believe that quality of life is precious and that no patient should be overlooked. We specialize in the sales and marketing of orphan drugs – those with a treatment population of less than 200,000 patients. Our company is committed to providing drug treatments for small numbers of patients with extremely rare medical conditions and diseases. While these drugs may not always save lives or cure diseases, they can vastly improve the lives of those with rare illnesses.





For more information:

Sigma-Tau Pharmaceuticals, Inc.

800 South Frederick Avenue, Suite 300

Gaithersburg, MD 20877

800-447-0169

301-948-1041

www.sigmataupharma.com



www.sigmatapharma.com